Press Releases April 30, 2026 04:05 PM

Jefferson Capital to Announce First Quarter 2026 Results

Jefferson Capital to Release Q1 2026 Financial Results and Host Webcast

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
JCAP

Jefferson Capital, Inc., a leading purchaser and manager of charged-off consumer accounts, will announce its first quarter 2026 financial results after market close on May 14, followed by a webcast to discuss the results. The company operates across the US, Canada, UK, and Latin America, servicing secured and unsecured assets for major creditors and financial institutions.

Jefferson Capital to Announce First Quarter 2026 Results
JCAP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Jefferson Capital specializes in purchasing and managing charged-off, insolvency, and active consumer accounts across multiple international markets.
  • The company serves a diverse client base including Fortune 500 creditors, fintech platforms, telecom providers, credit card issuers, and auto finance companies.
  • The Q1 2026 financial results announcement and webcast provide insights into Jefferson Capital's recent performance and business outlook.

MINNEAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (NASDAQ: JCAP) (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off, insolvency and active consumer accounts, today announced that it will release financial results for the first quarter 2026 after the market close on Thursday, May 14, followed by a webcast at 5:00 pm Eastern Time that day to discuss the Company’s results.

The live webcast and archived replay can be accessed in the investor relations section of the Company's website at https://investors.jcap.com/news-events/events.  

About Jefferson Capital, Inc.
Founded in 2002, Jefferson Capital is an analytically driven purchaser and manager of charged-off, insolvency and active consumer accounts with operations in the United States, Canada, the United Kingdom and Latin America. It purchases and services both secured and unsecured assets, and its growing client base includes Fortune 500 creditors, banks, fintech origination platforms, telecommunications providers, credit card issuers and auto finance companies. Jefferson Capital is headquartered in Minneapolis, Minnesota with additional offices and operations located in Sartell, Minnesota, Denver, Colorado and San Antonio, Texas (United States); Basingstoke, England, London, England and Paisley, Scotland (United Kingdom); London, Ontario and Toronto, Ontario (Canada); as well as Bogota (Colombia).

Contacts:

Investor Relations
IR@jcap.com


Risks

  • Financial results may be impacted by economic conditions affecting consumer credit quality and debt recovery rates, influencing profitability in financials and credit markets.
  • Operational risks include geographic diversification challenges across North America, the UK, and Latin America.
  • The company's performance is sensitive to regulatory changes in debt collection and consumer finance sectors across regions.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026